Entasis Therapeutics, a Waltham, Mass.-based leader in the discovery and development of anti-infective products, closed a $31.9m Series B-1 extension financing.
The financing expansion adds Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech to the original Series B funding round of $50m, which closed in March 2016, led by Clarus and including Frazier Healthcare Partners, Novo A/S and Eventide Funds. Tracy Saxton, Ph.D., Managing Partner at Pivotal, Heather Behanna, Ph.D., Principal at Sofinnova, and Heather Preston, M.D., Partner at TPG joined Entasis’ Board of Directors concurrent with the financing.
The company intends to use the funds to advance its pipeline of clinical and preclinical products targeting drug-resistant Gram-negative infections.
Led by Manos Perros, Ph.D., President and Chief Executive Officer, Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. The company’s anti-infective discovery platform has produced a pipeline of differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).